Journal Article

3′,4′-Dimethoxyflavone as an Aryl Hydrocarbon Receptor Antagonist in Human Breast Cancer Cells

Jeong-Eun Lee and Stephen Safe

in Toxicological Sciences

Volume 58, issue 2, pages 235-242
Published in print December 2000 | ISSN: 1096-6080
Published online December 2000 | e-ISSN: 1096-0929 | DOI: http://dx.doi.org/10.1093/toxsci/58.2.235
3′,4′-Dimethoxyflavone as an Aryl Hydrocarbon Receptor Antagonist in Human Breast Cancer Cells

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)

GO

Show Summary Details

Preview

Treatment of MCF-7 and T47D human breast cancer cells with 3′,4′-dimethoxyflavone (3′,4′-DMF) alone did not induce CYP1A1-dependent ethoxyresorufin O-deethylase (EROD) activity or reporter gene activity in cells transfected with an aryl hydrocarbon (Ah)-responsive construct (pRNH11c). In contrast, 1 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced up to a 50- to 80-fold increase in EROD and reporter gene activity in MCF-7 and T47D cells. In cells cotreated with 1 nM TCDD plus 0.1–10 μM 3′,4′-DMF, there was a concentration-dependent decrease in the TCDD-induced responses, with 100% inhibition observed at the 10 μM concentration. Gel mobility shift assays using rat liver cytosol and breast cancer cell nuclear extracts showed that 3′,4′-DMF alone did not transform the AhR to its nuclear binding form, but inhibited TCDD-induced AhR transformation in rat liver cytosol and blocked TCDD-induced formation of the nuclear AhR complex in MCF-7 and T47D cells. TCDD also inhibited estrogen-induced transactivation in MCF-7 cells, and this response was also blocked by 3′,4′-DMF, confirming the AhR antagonist activity of this compound in breast cancer cells.

Keywords: AhR; antagonist; breast cancer cells; 3′,4′-dimethoxyflavone

Journal Article.  5313 words.  Illustrated.

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.